

Samantha Pozzi, M.D.

Cancer Center, Policlinico di Modena
Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia
Italy

Born in Busto Arsizio (VA), Italy
August 07th 1970.
PZZSNT70M47B300R

Address:

Centro Oncologico, Padiglione Beccaria. Ingresso 33
Policlinico di Modena
Largo del Pozzo 71
41124 Modena (MO)
Italy
Tel: +39.059.422.5407
Email: samantha.pozzi@unimore.it

Settore scientifico disciplinare

MEDS-05/A Medicina interna

Education

- **Fellowship in Hematology**, with honors, University of Modena and Reggio Emilia; Modena, Italy, 2003
- **Medical Degree**, with honors, University of Pavia, Pavia, Italy, 1998
- **Diploma di Maturita' Scientifica**, Liceo Scientifico "A. Tosi"; Busto Arsizio, Italy

Work experience

- **Associate Professor MED/09**, University of Modena and Reggio Emilia, Italy, November 2015-present
- **Assistant Professor MED/09**, University of Modena and Reggio Emilia, Italy, December 2010-October 2015

- **Research Fellow**, Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute and Massachusetts General Hospital, Harvard Medical School, 2006-March 2011
- **Clinical Attendant/Clinical Researcher**, Program of Innovative Therapies in Oncology and Hematology, Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Italy, 2004-2006
- **Principal investigator and co-investigator** in phase II clinical trials for the treatment of Lymphoma and Myeloma, Gruppo Italiano Studio Linfomi (GISL), 2004-2006 and Fondazione Italiana Linfomi (FIL) 2011-present
- **Visiting Scholar**, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, September 2004-January 2005
- **Training in ICH-GCP** (Roche)

Academic/Teaching experience

- **Professor of Internal Medicine**, Dental Hygiene School, University of Modena and Reggio Emilia, Italy, 2018-present;
- **Professor of Internal Medicine**, Dental School, University of Modena and Reggio Emilia, Italy, 2015-present;
- **Professor of Clinical Methodology**, Medical School, University of Modena and Reggio Emilia, Italy, 2011-present;
- **Coordinator of the annual seminar “The role of the research nurse in clinical trials”**, Nursing School, University of Modena and Reggio Emilia, Italy, 2016
- **Mentor of post-graduate students** at University of Modena and Reggio Emilia, Italy
- **Mentor of graduate students** of Biotechnology, Nursing School and Medical School at the University of Modena and Reggio Emilia, Italy
- **Mentor of undergraduate students** for the CURE program (Continuing Umbrella of Research Experience), at Dana Farber Cancer Institute and Massachusetts General Hospital, Boston, USA Summer 2009-2010;
- **Supervisor** of undergraduate and graduate students in the translational research laboratory at the Department of Medical Oncology at Dana-Farber Cancer Institute and Massachusetts General Hospital, Boston, USA, 2006-2010;
- **Mentor of undergraduate students in biochemistry** , Medical School, University of Pavia, Italy, 1997

Grants and Awards

- Drug developments and development of nanotechnology for drug delivery systems (**external collaborator** in the PRIN 2010-2011- NANOMED - Area Scientifico-disciplinare 03: Scienze chimiche 100% - Coordinatore Scientifico: VASAPOLLO GIUSEPPE)

- **2009 Junior Grant of the International Myeloma Foundation** (IMF), Brian D. Novis Research Award: “Promoting osteoblastogenesis with a novel clinical grade Dkk-1 neutralizing antibody in the treatment of multiple myeloma bone disease”, USA
- **2005 Award For Young Researchers “Dr. Luppi”** , Modena, Italy

License and Membership

- **Member of the Italian Medical Association**, Ordine Provinciale dei Medici Chirurghi e degli Odontoiatri della Provincia di Vercelli, 1999-2017 (licence # 2552) and Ordine Provinciale dei Medici Chirurghi e degli Odontoiatri della Provincia di Modena 2017-present (licence # 7273)
- **Member of the Italian Lymphoma Study Group**, Gruppo Italiano Studio Linfomi, (GISL), 2004-2011
- **Member of the Italian Lymphoma Foundation** (Fondazione Italiana Linfomi-FIL), 2011-present
- **Member of the European Hematological Association** (EHA), 2008
- **Member of the Italian Society of Experimental Hematology** (Società Italiana di Ematologia Sperimentale-SIES), 2012-present
- **Member of the American Hematology Society** (ASH), 2014-present
- **Member of the Italian Society of Osteoncology** (ISO), 2017-present

Presentations

- “Cell-Penetrating CaCO₃ Nanocrystals for Improved Transport of NVP-BEZ235 across Membrane Barrier in T-Cell Lymphoma” in Nanoinnovation 2018 Conference and Exhibition, Rome, Italy, 11-14 September 2018
- “The therapy of the bone disease in multiple myeloma” I Meeting tri-regionale Emilia-Toscana-Liguria su gammopatie monoclonali e myeloma multiplo: specialisti a confronto con medici del territorio, Berceto (PR), Italy, 22/09/2018
- “Anti-RANK-L for the prevention of Cancer Treatment Bone Loss: when and why?”, meeting "Hot topics nel carcinoma della mammario ormonosensibile: questioni aperte dal setting adiuvante al contesto metastatico" Modena, Italy, 26/03/2018.
- “Monitoring bisphosphonate treatment in myeloma”: Multiple Myeloma and Related Malignancies - Bari, Italy, 3-5 November 2011
- “High dose zoledronic acid and bone remodeling: clinical insights translating back to the bench”; Center For Regenerative Medicine (CRM) meeting, Massachusetts General Hospital, September 2009
- “Promoting Osteoblastogenesis Using a Novel Dkk-1 Neutralizing Antibody in the Treatment of Multiple Myeloma Related Bone Disease”; webcast from the 50th Annual Meeting of the American Society of Hematology - ASH 2008; San Francisco

Third Mission

- “Stem cells and bone marrow transplant: what are they and what is their role?” Bondeno (MN), Italy, 28/04/2016
- Scaini-Sacchi-Pozzi: “Meet the Author: presentation of the book “Voglio Volare” by Luciana Scaini, Suzzara 1/10/2017
- “The evolution of the Therapies on Oncohematology”, Lions Club, 11/5/2018

Patent

International Patent Application No. PCT/US2015/063997

Title: COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND BENDAMUSTINE

Filing Date: December 04, 2015

Applicant: University of Modena and Reggio Emilia

Inventor: Samantha Pozzi, et al

Our Ref.: 575291: ACT-028PC

Protocols and clinical trials

- Principal investigator and co-investigator in several sponsored and IIT clinical trials in oncohemathology
- Study design and principal investigator of an in-vivo mouse model entitled “STUDIO IN VIVO MEDIANTE MODELLO MURINO DELLA AZIONE ANTINEOPLASTICA DI FARMACI INNOVATIVI IN AMBITO ONCOEMATOLOGICO” (expired on October 2015)
- Study design and principal investigator of a protocol to collect biological samples entitled: “Studi pre-clinici per la valutazione di nuovi farmaci/combinazioni farmacologiche ad azione antineoplastica nei linfomi”

Foreign Language

English: CEFR C1, C2

Publications

Articles in scientific journals:

Areas of interests

Lymphoma and Myeloma:

- Uccella S, Goteri G, Maiorana A, Donati V, Tibiletti MG, Magnoli F, Facchi S, Merchiori D, Morsia E, Papotti R, Bettelli S, Forti E, Galimberti S, Rupoli S, Filosa A, Dardanis D, Bomben R, Braglia L, **Pozzi S**, Sacchi S. Clinicopathological, cytogenetic, and molecular profiles of primary cutaneous diffuse large B-cell lymphomas. *Hum Pathol*. 2023 Jun;136:44-55. doi: 10.1016/j.humpath.2023.03.012. Epub 2023 Mar 28.
- Casadei B, Argnani L, Broccoli A, Patti C, Stefani PM, Cuneo A, Margiotta Casaluci G, Visco C, Gini G, Pane F, D'Alò F, Luzi D, Cantonetti M, **Pozzi S**, Musuraca G, Rosignoli C, Arcari A, Kovalchuk S, Tani M, Tisi MC, Petrini M, Stefoni V, Zinzani PL. Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter Folldela Study. *Cancers (Basel)*. 2022 Jan 27;14(3):654. doi: 10.3390/cancers14030654.
- Rigacci L, Battistini R, Kovalchuk S, Zoli V, Puccini B, Evangelista A, Arcaini L, Flenghi L, Visco C, Mian M, Di Rocco A, Peracchio C, Gotti M, Tisi MC, Palombi F, **Pozzi S**, Gioia D, Viero P, Martelli M. Obinutuzumab does not improve complete methabolic response but does not compromise mobilization or engraftment of autologous peripheral blood stem cells in diffuse large B cell lymphoma: Results from a fondazione italiana linfomi prospective phase II study (the GIOTTO study). *Hematol Oncol*. 2022 Oct;40(4):609-616. doi: 10.1002/hon.3028. Epub 2022 Jun 5.
- Cosenza M, Sacchi S, **Pozzi S**. Cytokine Release Syndrome Associated with T-Cell-Based Therapies for Hematological Malignancies: Pathophysiology, Clinical Presentation, and Treatment. *Int J Mol Sci*. 2021 Jul 17;22(14):7652. doi: 10.3390/ijms22147652.
- Bettelli S, Marcheselli R, **Pozzi S**, Marcheselli L, Papotti R, Forti E, Cox MCC, Di Napoli A, Tadmor T, Mansueto GR, Musto P, Flenghi L, Quintini M, Galimberti S, Lalinga V, Donati V, Maiorana A, Polliack A, Sacchi S. Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting. *Leuk Res*. 2021 May;104:106552. doi: 10.1016/j.leukres.2021.106552. Epub 2021 Feb 27.
- Rigacci L, Annibali O, Kovalchuk S, Bonifacio E, Pregnotato F, Angrilli F, Vitolo U, **Pozzi S**, Broggi S, Luminari S, Merli F, Spina M, Bolis S, Margiotta-Casaluci G, Scalzulli R, Cox C, Mamusa AM, Santoro A, Zinzani PL, Ferrari S, Gini G, Vigliotti ML, Mulè A, Flenghi L; Fondazione Italiana Linfomi (FIL). Nonpegylated liposomal doxorubicin combination regimen (R-COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity. *Hematol Oncol*. 2020 Oct;38(4):478-486. doi: 10.1002/hon.2764. Epub 2020 Jul 9.
- Marcheselli R, Bari A, Tadmor T, Marcheselli L, Cox MC, Papotti R, Ferrari A, Baldini L, Gobbi P, Levy I, Pugliese G, Federico M, Polliack A, **Pozzi S**, Sacchi S. Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma. *Hematol Oncol*. 2020 Oct;38(4):439-445. doi: 10.1002/hon.2757. Epub 2020 Jun 17.
- Cosenza M, Civallero M, Marcheselli L, Sacchi S, **Pozzi S**. Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination. *Apoptosis*. 2020 Jun;25(5-6):370-387. doi: 10.1007/s10495-020-01607-3.

- Marcheselli R, Franceschetto A, Sacchi S, Bari A, Levy I, Pizzichini P, Prosperi D, D'Apollo R, Massi L, Casolo A, **Pozzi S**, Marcheselli L, Tadmor T, Prandini N, Cox MC. The prognostic role of end of treatment FDG-PET-CT in patients with diffuse large B cell lymphoma can be improved by considering it with absolute monocyte count at diagnosis. *Leuk Lymphoma*. 2019 Aug;60(8):1958-1964. doi: 10.1080/10428194.2018.1564049. Epub 2019 Jan 28.
- Marcheselli R, Franceschetto A, Sacchi S, Bari A, Levy I, Pizzichini P, Prosperi D, D'Apollo R, Massi L, Casolo A, **Pozzi S**, Marcheselli L, Tadmor T, Prandini N, Cox MC. The prognostic role of end of treatment FDG-PET-CT in patients with diffuse large B cell lymphoma can be improved by considering it with absolute monocyte count at diagnosis. *Leuk Lymphoma*. 2019 Jan 28:1-7. doi: 10.1080/10428194.2018.1564049. PMID: 30689474
- Bari A, Marcheselli L, Marcheselli R, **Pozzi S**, Cox MC, Baldessari C, Ferri P, Gobbi P, Baldini L, Tadmor T, Musto P, Federico M, Sacchi S. Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients. *Br J Haematol*. 2018 Feb;180(4):600-602. doi: 10.1111/bjh.14406. Epub 2016 Oct 26. PMID: 2778578
- Marcheselli R, Marcheselli L, Cortesi L, Bari A, Cirilli C, **Pozzi S**, Ferri P, Napolitano M, Federico M, Sacchi S. Risk of Second Primary Malignancy in Breast Cancer Survivors: A Nested Population-Based Case-Control Study. *J Breast Cancer*. 2015 Dec;18(4):378-85. doi: 10.4048/jbc.2015.18.4.378. Epub 2015 Dec 23. PMID: 26770245
- **Pozzi S**, Marcheselli L, Bari A, Liardo EV, Marcheselli R, Luminari S, Quaresima M, Cirilli C, Ferri P, Federico M, Sacchi S. Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis. *Br J Haematol*. 2013 Oct;163(1):40-6. doi: 10.1111/bjh.12465. Epub 2013 Jul 27. PMID: 23889344
- **Pozzi S**, Gentile M, Sacchi S, Marcheselli R, Corso A, Cocito F, Musto P, Guarini A, Minoia C, Vincelli I, Ria R, Rivolti E, Mele G, Bari A, Mazzone C, Badiali S, Marcheselli L, Palumbo A, Morabito F. Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study. *Leuk Lymphoma*. 2017 Mar;58(3):552-559. doi: 10.1080/10428194.2016.1205741. Epub 2016 Jul 21. PMID: 27442600
- **Pozzi S**, Raje N. The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future. *Oncologist*. 2011;16(5):651-62. doi: 10.1634/theoncologist.2010-0225. Epub 2011 Apr 14. Review. PMID: 21493759

Osteonecrosis of the Jaw:

- **Pozzi S**, Marcheselli R, Falorio S, Masini L, Stelitano C, Falcone A, Quarta G, Ponchio L, Pitini V, Luminari S, Baldini L; Gruppo Italiano Studio Linfomi (GISL). Bisphosphonates-associated osteonecrosis of the jaw: A long-term follow-up of a series of 35 cases observed by GISL and evaluation of its frequency over time. *Am J Hematol*. 2009 Dec;84(12):850-2. doi: 10.1002/ajh.21553. PMID: 19862827
- **Pozzi S**, Marcheselli R, Sacchi S, Baldini L, Angrilli F, Pennese E, Quarta G, Stelitano C, Caparotti G, Luminari S, Musto P, Natale D, Broglia C, Cuoghi A, Dini D, Di Tonno P, Leonardi G, Pianezze G, Pitini V, Polimeno G, Ponchio L, Masini L, Musso M, Spriano M, Pollastri G; Gruppo

Italiano Studio Linfomi. Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients. *Leuk Lymphoma*. 2007 Jan;48(1):56-64. PMID: 17325848

Translational Reserach

- Cosenza M, **Pozzi S**. The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease. *Int J Mol Sci*. 2018 Aug 9;19(8). pii: E2337. doi: 10.3390/ijms19082337. Review. PMID: 30096875
- Civallero M, Cosenza M, **Pozzi S**, Sacchi S. Ruxolitinib combined with vorinostat suppresses tumor growth and alters metabolic phenotype in hematological diseases. *Oncotarget*. 2017 Oct 23;8(61):103797-103814. doi: 10.18632/oncotarget.21951. eCollection 2017 Nov 28. PMID: 29262601
- Cosenza M, Civallero M, Marcheselli L, Sacchi S, **Pozzi S**. Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine. *Apoptosis*. 2017 Jun;22(6):827-840. doi: 10.1007/s10495-017-1364-4. PMID: 28315173
- **Pozzi S**, Fulciniti M, Yan H, Vallet S, Eda H, Patel K, Santo L, Cirstea D, Hideshima T, Schirtzinge L, Kuhstoss S, Anderson KC, Munshi N, Scadden D, Kronenberg HM, Raje N. In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma. *Bone*. 2013 Apr;53(2):487-96. doi: 10.1016/j.bone.2013.01.012. Epub 2013 Jan 17.
- **Pozzi S**, Vallet S, Mukherjee S, Cirstea D, Vaghela N, Santo L, Rosen E, Ikeda H, Okawa Y, Kiziltepe T, Schoonmaker J, Xie W, Hideshima T, Weller E, Boussein ML, Munshi NC, Anderson KC, Raje N. High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. *Clin Cancer Res*. 2009 Sep 15;15(18):5829-39. doi: 10.1158/1078-0432.CCR-09-0426. Epub 2009 Sep 8. PMID: 19737962

Nanotechnologies:

- Vergaro V, Civallero M, Citti C, Cosenza M, Baldassarre F, Cannazza G, **Pozzi S**, Sacchi S, Fanizzi FP, Ciccarella G. Cell-Penetrating CaCO₃ Nanocrystals for Improved Transport of NVP-BEZ235 across Membrane Barrier in T-Cell Lymphoma. *Cancers (Basel)*. 2018 Jan 25;10(2). pii: E31. doi: 10.3390/cancers10020031.

Book chapters:

- Pozzi S, Anesi A, Generali L, Bari A, Consolo U, Chiarini L. Bisphosphonates-related osteonecrosis of the jaw (BRONJ). *Complications in Endodontic Surgery 2014*, Springer Ed. Chapter 14, 153-165

Modena, 01/10/2024

